Literature DB >> 8395518

Xenopus muscle acetylcholine receptor alpha subunits bind ligands with different affinities.

Y D Wang1, T Claudio.   

Abstract

The acetylcholine receptor (AChR) from vertebrate skeletal muscle is a pentameric complex composed of two identical alpha (the ligand-binding subunit) and one each of beta, gamma, and delta subunits. All muscle-like alpha subunits appear to be encoded by a single gene except for Xenopus where two genes have been identified (X alpha 1a and X alpha 1b). By establishing stable cell lines expressing each Xenopus alpha subunit plus Torpedo beta gamma delta (XaT and XbT), we were able to investigate immunological and ligand-binding properties of these two Xenopus subunits. We determined that each subunit was capable of proper assembly with beta gamma delta subunits, each hybrid AChR cell line responded to bath-applied acetylcholine as determined by 22Na+ influx, but the two hybrid AChRs had distinct ligand-binding properties. The most striking difference between the two hybrids was observed with alpha-bungarotoxin (BuTx) binding. The KD for BuTx binding to XbT hybrids was virtually identical to that of Torpedo and most other muscle AChRs, approximately 10(-10)-10(-11) M. The KD for BuTx binding to XaT hybrids, however, was approximately 1000-fold weaker (6 x 10(-8) M). This weak binding was due primarily to a very rapid BuTx off-rate (4.4 x 10(-2) s-1 for XaT AChRs compared with approximately 1.6 x 10(-5) s-1 for all-Torpedo and XbT AChRs).

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395518

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  2 in total

1.  Formation of the nicotinic acetylcholine receptor binding sites.

Authors:  W N Green; C P Wanamaker
Journal:  J Neurosci       Date:  1998-08-01       Impact factor: 6.167

2.  Evolution of vertebrate nicotinic acetylcholine receptors.

Authors:  Julia E Pedersen; Christina A Bergqvist; Dan Larhammar
Journal:  BMC Evol Biol       Date:  2019-01-30       Impact factor: 3.260

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.